Perkin-Elmer To Collaborate on Bioinformatics Research With SmithKline Beecham

October 24, 1996

NORWALK, CT, October 11, 1996 -- The Perkin-Elmer Corporation (NYSE:PKN) has announced a research collaboration with SmithKline Beecham (NYS:SBH) to develop automated data management and analysis systems that will speed the drug discovery process for the pharmaceutical industry. These systems will help pharmaceutical researchers to manage and automatically analyze the vast amounts of data generated by the ABI PRISM DNA analysis systems developed and produced by Perkin-Elmer's PE Applied Biosystems Division, facilitating the identification of potential targets for new therapies.

Under the terms of the agreement, SmithKline Beecham will receive access to analysis and development tools for the ABI PRISM BioLIMS (laboratory information management system) as well as the sample file database that was exclusively developed for PE Applied Biosystems by Molecular Informatics of Santa Fe. In return, SmithKline Beecham will provide development support for the BioLIMS and will aid in developing functional specifications for future products. As a result of the collaboration, Perkin-Elmer hopes to develop sophisticated systems for data collection, analysis, and management that it can market to the pharmaceutical industry.

"Managing and analyzing tremendous amounts of information is the next critical step in moving the value of genetic research from the research lab to the patient," explained Steve Lombardi, PE Applied Biosystems' Vice President of Genetic Analysis. "SmithKline Beecham, a visionary in understanding the role that bioinformatics will play in all aspects of molecular medicine, is an ideal partner in this effort." "To be competitive in today's pharmaceutical industry, the ability to rapidly collect and analyze data is critical," according to David Searls, SmithKline Beecham's Group Director for Bioinformatics. "Our collaboration with Perkin- Elmer is an exciting development that promises to markedly improve the efficiency with which we are able to process our genomic data. By combining PE Applied Biosystems' new automation and analysis software with our own in-house bioinformatics expertise, we expect to significantly reduce the time required to integrate new sequence data into the critical initial states of target discovery."

For nearly 10 years, PE Applied Biosystems, headquartered in Foster City, California, has been a leader in the automation of DNA sequencing and genetic analysis systems, which have made possible major discoveries in cancer research and in the characterization of major genetic diseases. Perkin-Elmer is the world leader in the development, manufacture, and marketing of life science systems and analytic instruments used in markets such as biotechnology, pharmaceuticals, environmental testing, food, agriculture, and chemical manufacturing.

Headquartered in Connecticut, Perkin-Elmer had revenues of more that $1.1 billion in fiscal year 1996 and employs 5,700 people worldwide. Information about Perkin-Elmer is available on the World Wide Web at http://www.perkin- elmer.com or by phoning (800) 762-6923.
"Managing and analyzing tremendous amounts of information is the next critical step in moving the value of genetic research from the research lab to the patient," explained Steve Lombardi, PE Applied Biosystems' Vice President of Genetic Analysis. "SmithKline Beecham, a visionary in understanding the role that bioinformatics will play in all aspects of molecular medicine, is an ideal partner in this effort."

PerkinElmer Inc.

Related Bioinformatics Articles from Brightsurf:

Glyphosate may affect human gut microbiota
More than half of bacterial species in the core of the human gut microbiome are potentially sensitive to glyphosate, shows new research.

Next-gen bioinformatics tool enables big data analysis without programming expertise
A new data analysis tool developed by MD Anderson researchers incorporates a user-friendly, natural-language interface to aid biomedical researchers without bioinformatics or programming expertise to conduct intuitive data.

Embracing bioinformatics in gene banks
Scientists from the IPK have explored, within a perspective paper, the upcoming challenges and possibilities of the future of gene banks.

New bioinformatics tool identifies and classifies CRISPR-Cas systems
Designed to improve the utility and availability of increasingly diverse CRISPR-Cas genome editing systems, the new CRISPRdisco automated pipeline helps researchers identify CRISPR repeats and cas genes in genome assemblies.

AMP Iissues consensus guideline recommendations for NGS bioinformatics pipelines
The Association for Molecular Pathology, the premier global, non-profit molecular diagnostics professional society, today published 17 consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better patient care.

Advances: Bioinformatics applied to development & evaluation of boron-containing compounds
The interest for developing boron-containing compounds as drugs is increasing after some successful cases.

When life sciences become data sciences
The University of Freiburg offers Europe-wide infrastructure and service in Bioinformatics.

Bioinformatics brings to light new combinations of drugs to fight breast cancer
A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.

New bioinformatics tool tests methods for finding mutant genes that 'drive' cancer
Computational scientists and cancer experts have devised bioinformatics software to evaluate how well current strategies distinguish cancer-promoting mutations from benign mutations in cancer cells.

EDGE bioinformatics brings genomics to everyone
A new bioinformatics platform called Empowering the Development of Genomics Expertise (EDGE) will help democratize the genomics revolution by allowing users with limited bioinformatics expertise to quickly analyze and interpret genomic sequence data.

Read More: Bioinformatics News and Bioinformatics Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.